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Butadiene (BD), a ﬂammable gas with a pun-
gent odor, is used in the manufacture of
styrene-butadiene rubber and other polymers.
BD is a four-carbon compound with two
double bonds that can be oxidized to epox-
ides, which can then rearrange to form reac-
tive metabolites. In 1995 BD ranked 36th in
U.S. production volume at 3.68 billion
pounds (1). 
Butadiene is carcinogenic in rodents.
Female mice developed lung tumors after
chronic exposure of only 6.25 ppm. At
higher dose levels the mice developed tumors
at multiple sites, including the hematopoi-
etic system, lungs, forestomach, heart, mam-
mary glands, and ovaries (2). Rats appear to
be less sensitive but developed tumors in sev-
eral organs including the pancreas, testes,
uterus, and the mammary, zymbal, and thy-
roid glands at chronic exposure levels of
1,000 ppm (3). 
In human epidemiologic studies there
have been a number of reports of increased
mortality rates in BD-exposed workers due to
malignancies of the hematopoietic system (4).
In these studies, however, there have been
inconsistencies in the types of malignant
tumors and in the relationship of tumor inci-
dence to BD exposure level, duration of expo-
sure, and time period of exposure (World
War II vs. the postwar period) (5,6). 
Butadiene has been shown to be geno-
toxic in both in vitro and in vivo laboratory
tests. BD was mutagenic in Salmonella
typhimurium strain TA 1530 with metabolic
activation (7), and BD gas was weakly muta-
genic in the mouse lymphoma assay in the
presence of rat liver S9 (8). In laboratory
animals, BD can induce chromosomal dam-
age and somatic cell mutations. The most
sensitive cytogenetic end point in mice
appears to be sister chromatid exchanges.
These were induced in bone marrow by a
10-day exposure to 6.25 ppm BD (9). In the
same study, bone marrow micronuclei were
induced at 62.5 ppm and chromosome aber-
rations at 625 ppm (9). At BD doses as low
as 50 ppm for 5 days, micronuclei were
induced in both bone marrow and periph-
eral blood erythrocytes (10). Exposure of
mice to BD doses as low as 20 ppm for 4
weeks induced gene mutations at the HPRT
locus in spleen lymphocytes (11,12) and in
thymic lymphocytes (12). In transgenic
mice, exposures to 62.5 ppm of BD for 4
weeks resulted in increased frequencies of
mutations at the lacI locus in bone marrow
cells (13). Rats appear to be much less sensi-
tive to BD-induced chromosomal damage
(14) and mutation (12) when compared to
mice. This is consistent with the observed
carcinogenic effects in the two species.
The carcinogenic and mutagenic effects
of BD are thought to be due to the forma-
tion of the epoxide metabolites butadiene
monoepoxide (EB), butadiene diepoxide
(DEB), and butadiene diolepoxide (EBD).
All three epoxide metabolites are mutagenic
both in vitro and in vivo. Of the three, DEB
is the most potent mutagen; it is 4–12 times
more potent than EB in the Ames/Salmonella
assay (15) and 100 times more potent in
human TK6 lymphoblasts (16). EBD was of
intermediate potency in these in vitro assays
(15,16). In vivo, the three epoxides induced
increased frequencies of bone marrow
micronuclei in the following order of
potency: DEB > EB > EBD (15). The muta-
genic potency of BD, EB, and DEB at the
HPRT locus was determined in mice and rats
by Meng et al. (17). EB was mutagenic in
mice but not in rats, whereas DEB was more
potent in rats than in mice. 
The differences in carcinogenic responses
between rats and mice and weaknesses in
some of the human epidemiologic studies
have resulted in controversies regarding the
probable carcinogenic risks of BD to humans
(6,18). It is difﬁcult to know which animal
model might best be used to estimate human
risk (if either), and it is unlikely that the epi-
demiologic record can be improved in the
near future. Industry responded in the late
1980s to concerns about the carcinogenicity
of BD by initiating steps to reduce exposures.
The Occupational Safety and Health
Administration (OSHA) promulgated a new
permissible exposure limit in 1996, reducing
the 8-hr time-weighted average exposure limit
from 1,000 ppm BD to 1 ppm (19). New
epidemiologic studies, designed to detect car-
cinogenic effects at these low concentrations,
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Articles
1,3-Butadiene (BD), which is used to make styrene-butadiene rubber, is a potent carcinogen in
mice and a probable carcinogen, associated with leukemia, in humans. We have previously used
HPRT mutation as a biomarker to evaluate exposures to BD in a monomer production plant. We
now report on a study of 49 workers in a styrene-butadiene rubber plant in which we used the
concentration of the BD metabolite 1,2-dihydroxy-4-(N-acetylcysteinyl-S)-butane (M1) in urine
as a biomarker of exposure and the frequency of HPRT variant (mutant) lymphocytes (Vf) as a
biomarker of effect. Workers were assigned to high- and low-exposure groups based on historical
information about work areas and jobs. Personal exposure to BD for one work shift was measured
using a passive badge dosimeter. Each participant provided a urine specimen and blood sample at
the end of the work shift and completed a questionnaire providing information on lifestyle,
health, and work activities. The average BD exposures in the high- and low-exposure groups were
signiﬁcantly different, even after excluding two extreme values, (high 1.48 ppm; low 0.15 ppm, p
< 0.002). This study was done in 1994 and 1995 before the establishment, in 1996, of the new
permissible exposure limit of 1 ppm. Both the mean M1 and the HPRT Vf were more than three
times greater in the high-exposure group than in the low-exposure group (p < 0.0005). The three
end points correlated with each other, with sample correlation coefﬁcients between 0.4 and 0.6.
The correlations among BD exposure and the biomarkers of internal exposure and genotoxicity
suggest that occupational exposure to BD, in the range of 1–3 ppm, may be associated with
adverse biological effects. Key words: biological monitoring, butadiene, HPRT mutations, occupa-
tional health. Environ Health Perspect 110:1249–1255 (2002). [Online 28 November 2001]
http://ehpnet1.niehs.nih.gov/docs/2002/110p1249-1255ammenheuser/abstract.htmlwould require very large cohorts to achieve
adequate statistical power. Also, disease out-
comes following extended chronic exposure,
based on workers not exposed to earlier
higher concentrations of BD, will not be
available for several decades. 
A more appropriate approach for current
investigations of the effects of BD exposure
would be to use biological markers as out-
come measures in human population studies.
Because BD and its metabolites are genotoxic
in animal studies, genotoxicity tests can be
useful as effect biomarkers in studies of pop-
ulations of exposed workers. Also, by using a
biomarker of internal exposure, such as the
level of a urinary metabolite of BD, associa-
tions between exposure and the genotoxic
effects of exposure can be identified.
Although somatic cell genotoxicity is not an
adverse health outcome in itself, genotoxic
effects are mechanistically linked to neopla-
sia. Because of this linkage, evidence that
exposure to a suspected carcinogen is associ-
ated with genotoxicity suggests that a pre-
ventable risk might exist. In the early 1990s
we conducted a preliminary study of a small
cohort of workers in a BD monomer plant.
We found that workers with exposure of
about 1–3 ppm BD had a 3-fold elevation in
the frequency of variant (mutant) lympho-
cytes in the autoradiographic HPRT mutant
lymphocyte assay compared to less-exposed
workers and nonexposed, outside controls
(20). This increase correlated with an eleva-
tion in the concentration of a conjugated
metabolite derived from EB [1,2-dihydroxy-
4-(N-acetylcysteiny1-S-)-butane], called
“M1.” No increase was observed in chromo-
some aberrations using conventional cytoge-
netic assays, although a small increase in
chromosomal damage was detected in cells
from the higher exposed group compared to
the low- or nonexposed groups after an in
vitro challenge with X rays (21). A follow-up
study at this same monomer plant a few
months later conﬁrmed the observation of an
increased HPRT variant frequency (Vf) (22). 
We have now conducted a study of a
larger group of workers in a styrene-butadi-
ene rubber manufacturing facility in south-
east Texas. Our objective was to determine
whether the earlier observations could be
conﬁrmed in a different occupational setting.
In this study, conducted in 1994–1995, the
exposure of workers to BD was measured
using personal organic vapor monitors. The
urine M1 metabolite of BD, and the fre-
quency of HPRT mutant lymphocytes were
measured as biomarkers of internal exposure
and effect, respectively. We report here that,
in workers with higher exposures to BD, we
confirm our earlier observation of an
increased urine M1 concentration and an
elevation in HPRT Vf. 
Materials and Methods
Chemicals and media. Reagents and media for
cell culture were obtained from the following
suppliers: 6-thioguanine (TG), citric acid, and
dimethyl sulfoxide (DMSO) were obtained
from Sigma (St. Louis, MO); phytohemagglu-
tinin (PHA), reagent grade, from Murex (HA
15, 45 mg/5 mL bottle; Dartford, England),
RPMI 1640 medium, penicillin-strepto-
mycin, and L-glutamine from GIBCO-BRL
(Gaithersburg, MD); HL-1 medium supple-
ment from Bio-Whittaker (Walkersville,
MD); and fetal bovine serum (FBS) from
HyClone Laboratories (Logan, UT). NTB-2
autoradiographic emulsion and D-19 devel-
oper were obtained from Kodak (Rochester,
NY) and [3H]-thymidine (3H-TdR) was
obtained from from ICN (Costa Mesa, CA).
Study design. This study was designed
to evaluate the possible genotoxic effects of
working in a styrene-butadiene rubber plant
in southeast Texas. Workers were recruited
with a letter that explained the purpose and
design of the study and asked for their par-
ticipation. Those who agreed to participate
completed a short form attached to the let-
ter to enroll in the study. Each volunteer
also signed a consent form approved by the
human subject Institutional Review Board
of the University of Texas Medical Branch.
Participants then completed a questionnaire
which provided information on the follow-
ing subjects: personal description (age, eth-
nicity, sex); history of tobacco use and
customary use of alcohol and caffeine-con-
taining beverages; health status and medica-
tion use; and work-related information
including job title, work locations, and
occupational history. Each participant was
asked to wear a 3M 3520 organic vapor
monitor (3M, St. Paul, MN), which served
as a passive dosimeter, for one work shift (8
hr) to measure exposure to butadiene and
styrene. At the end of the shift, a urine spec-
imen and a blood sample of approximately
70 mL was collected. Before the collection
of personal exposure data and biological
samples, we divided the workers into two
groups based on historical butadiene expo-
sure levels in different work areas. A pilot
exposure assessment was consistent with this
assignment. Workers in the reactor, recov-
ery, tank farm, and laboratory areas were
assigned to the high-exposure group.
Workers in the blending, coagulation, bal-
ing, shipping, control room, and utility
areas were assigned to the low-exposure
group. The primary end points analyzed
were the time-weighted average exposure to
butadiene in breathing zone air, the concen-
tration of the M1 metabolite in urine, and
the HPRT Vf in lymphocytes. We con-
firmed smoking status by measuring coti-
nine in blood plasma.
Exposure assessment. Organic vapor mon-
itors (OVM; 3M 3520) with two charcoal
layers were used as passive badge dosimeters.
The sealed containers were opened immedi-
ately before giving the monitor to a partici-
pant, who wore it attached to clothing near
the face for the entire work shift. Workers
carried a two-page diary form during the day
to record their work location and activities for
each hour of the shift. For each hour of the
shift, the workers were asked to characterize
their chemical exposure as about typical for
their jobs, higher, or lower than typical. They
were also asked to indicate whether they wore
a respirator during that hour and to record
any unusual events. At the end of the shift the
workers reported back to the study site and
turned in the OVM, which was immediately
capped, placed in its canister, and stored in an
ice chest. The OVMs were shipped to an ana-
lytical laboratory (NATELSCO, Long Grove,
IL) for extraction and analysis by gas chro-
matography. The minimum time-weighted
average exposure that could be reliably calcu-
lated with this method was about 0.25 ppm
for butadiene and about 1 ppm for styrene. 
Urine analysis. A single urine specimen
of up to 200 mL was collected in one or two
polypropylene specimen containers at the
end of the work shift. Specimens were imme-
diately frozen on dry ice. They were stored in
the laboratory at –20oC until shipped on dry
ice to the Inhalation Toxicology Research
Institute (now Lovelace Respiratory Research
Institute) in Albuquerque, New Mexico.
They were analyzed there for the M1
metabolite as described previously (23).
Briefly, deuterated standards were added to
aliquots of the samples, which were then
extracted and analyzed by selective ion moni-
toring in a Hewlett-Packard gas chromato-
graph, mass spectrometer (Hewlett-Packard,
Palo Alto, CA). Creatinine levels were also
determined to normalize for the dilution
effects of ﬂuid consumption.
Lymphocyte and plasma isolation and
cryopreservation. A blood sample from each
worker was collected in ﬁve 15-mL sodium
heparinized vacuum tubes (Becton-
Dickinson, Franklin Lakes, NJ). Samples
were returned to the laboratory within 4–12
hr of collection. Mononuclear cells and
plasma were separated from the whole blood
by density centrifugation on Histopaque
(Sigma). The lymphocytes were washed,
counted, and cryopreserved, as previously
described (24). Cells were frozen at 10–15 ×
106 cells per 1-mL cryotube in 50% FBS,
10% DMSO, and 40% RPMI 1640. An
average of 6 cryotubes per subject were pre-
pared and stored in liquid nitrogen until
ready for use.
A 2-mL aliquot of plasma from each
blood sample was frozen at –20°C in glass
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ratory of Helen Van Vunakis (Brandeis
University, Waltham, MA). The plasma was
analyzed for cotinine concentration by
radioimmunoassay (25). Cotinine concen-
trations > 20 ng/mL of plasma were consid-
ered indicative of active tobacco use. The
remaining plasma from the blood was frozen
for later use as an autologous growth supple-
ment in the HPRT assay.
The HPRT mutant lymphocyte assay. We
determined the frequencies of HPRT variant
(mutant) lymphocytes using the short-term
autoradiographic assay. Detailed methods
have been described previously (26,27).
Assays were performed with coded samples so
that the exposure status of the subjects was
unknown. Three or four cryotubes (about
30–45 × 106 cells) were thawed, washed,
counted, and resuspended in growth medium
(RPMI 1640 with antibiotics, 2% reagent
grade PHA, 20% HL-1, 25% autologous
plasma). Five to 6 million lymphocytes were
aliquoted into each of 5–8 vented flasks
(Falcon No. 3108, Lincoln Park, NJ) and 6-
thioguanine was added. The final TG con-
centration was 2 × 10–4 M and the ﬁnal cell
density was 1 × 106/mL. One labeling index
(LI) ﬂask was prepared without TG. After a
24-hr incubation at 37°C, all cultures were
labeled with 25 µCi of [3H]-TdR, incubated
for an additional 18 hr, and harvested by
adding 9 mL of chilled 0.1 M citric acid to
each ﬂask. The free nuclei from the TG-con-
taining flasks were washed with methanol-
acetic acid ﬁxative and resuspended in 1 or 2
tubes in 0.25 mL fixative. The nuclei from
the LI flask were harvested separately using
the same procedure. A 20-µL aliquot from
each tube from the TG-containing cultures
was counted with a particle counter (Coulter,
Hialeah, FL), and all of the remaining nuclei
in the tube were placed on an 18 × 18 mm
coverslip afﬁxed to the end of a microscope
slide. The nuclei from the LI flask were
counted and an aliquot of about 0.15 × 106
cells was spread evenly onto a separate 18 ×
18 mm coverslipped slide.
Slides were stained with aceto-orcein,
dipped in NTB-2 emulsion, stored for 2–3
days in light-tight boxes at 4°C, and devel-
oped with D-19. Coded slides were read with
a Nikon Labophot microscope (Nikon,
Tokyo, Japan), and a count was made of all
labeled cells from the TG-containing cultures.
For the LI slide, a random differential count
was made of 3,000 labeled and unlabeled cells
to provide an estimate of the proportion of
normal (nonmutant) lymphocytes from each
subject that were able to grow in culture. The
Vf is calculated by taking the total of the
labeled cells identified on the slides derived
from the TG-containing cultures and divid-
ing this number by the LI multiplied by the
number of nuclei initially added to the TG
slides. The denominator for this calculation is
referred to as the number of evaluatable cells.
Statistical analysis. The parameters
obtained for analysis were time-weighted
average exposure to butadiene in parts per
million, concentration of the M1 metabolite
in urine in nanograms per milligram creati-
nine, and the HPRT Vf in variant cells per
106 evaluatable lymphocytes.  For group
comparisons, results were analyzed by expo-
sure group and smoking status. Differences
between groups were analyzed using the
unpooled variance version of the independent
two-sample Student’s t-test from the Minitab
statistical package (Minitab Inc., State
College, PA). We also used the nonparamet-
ric Wilcoxon rank test (S-Plus, Insightful
Corporation, Seattle, WA) for comparison.
The relationships between parameters were
analyzed for correlations by means of the
Fisher z-test for significance and associated
conﬁdence intervals as implemented in the S-
Plus statistical program 
Results
Study population. A total of 63 workers (31
in high-exposure areas and 32 in low-expo-
sure areas) initially enrolled in the study and
participated in blood sample collection. Of
these, seven high-exposure and six low-expo-
sure subjects were eliminated because their
lymphocyte cultures had low LIs (< 5%)
and/or low cell recovery after freezing. This
resulted in insufﬁcient numbers of evaluatable
cells (< 0. 4 × 106) available to perform an
adequate assay for detecting frequencies of
HPRT mutant cells. HPRT mutant frequen-
cies were obtained from 24 high-exposure and
25 low-exposure subjects (one low-exposure
nonsmoker had an adequate LI but no labeled
cells on slides from the TG-containing 
cultures). Badge dosimeter measurements of
BD exposure were obtained from 48 workers:
24 in high-exposure and 24 in low-exposure
areas. Urine analyses for M1 were obtained
for 47 participants (24 high and 23 low). 
The demographic data are presented in
Table 1. All of the evaluated workers were
either white, non-Hispanic (75.5%), or
African American (24.5%). The workers in
the high-exposure areas were about 5 years
older and had worked in the plant about 7
years longer than the workers in the low-
exposure areas. In both groups about 80% of
the workers were nonsmokers. Five individu-
als in the high-exposure group and three in
the low-exposure group were tobacco chew-
ers (resulting in elevations of plasma cotinine
levels). All other subjects classed as nonsmok-
ers had plasma cotinine levels < 20 ng/mL.
Results by exposure groups. The results
for BD exposure levels, urine metabolites,
and HPRT mutant lymphocytes were com-
pared for the high- and low-exposure groups
(Table 2). The minimum concentration of
BD in air for which a concentration could be
reported, after an 8-hr measurement, was
approximately 0.25 ppm. Out of 24 determi-
nations included in the data set for workers
in the high-exposure areas, 16 produced mea-
surable values and 8 were below the detection
limit. For the 24 samples from workers in the
low-exposure areas, only 2 (0.27 and 0.51
ppm) were above the detection limit, and the
remainder were below. The average BD
exposure levels for the different work areas
are shown in Figure 1. For the purpose of
calculating averages, a value of one-half of the
minimum detection limit (0.125 ppm) was
used for subjects whose exposures were below
the detection limit. Two extreme values were
omitted from Figure 1. One of these
involved a laboratory worker who reported
spilling BD-contaminated water on his cloth-
ing. He had a badge value that day of 20.8
ppm BD. The other subject was a mainte-
nance worker who reported high exposure to
BD while opening a line. His badge value
was 23 ppm, but he wore a respirator during
this operation. Neither of these unusually
high BD values is likely to represent day-to-
day exposure or be representative of the study
population as a whole. 
Styrene exposures were also determined.
However, the minimum concentration that
could be calculated for an 8-hr exposure was
1 ppm, and most exposures were < 1 ppm.
Based on the actual mass of analyte mea-
sured from each badge, the molar ratios of
BD to styrene had a mean (± SEM) of 27.92
± 7.22. Thus, BD exposures were substan-
tially greater than styrene levels.
Table 2 presents group means for the
effect and exposure biomarkers. A clear dis-
tinction was observed between the high- and
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Table 1. Descriptive characteristics of the study population.
High exposure Low exposure
Number enrolled  31 32
Number evaluated  24 25
Mean age ± SD (n) 46.7 ± 10.0 (22) 41.6 ± 9.9 (24)
Work longevity ± SD (n) 20.9 ± 10.7 (23) 14.0 ± 12.2 (24)
Non-Hispanic white  19 18
African American 5 7
Smokers 5 5
Nonsmokers 19 20low-exposure areas. The mean BD exposure
value (± SE) for the high-exposure areas was
1.48 ± 0.37 ppm (excluding the two extreme
values) with a range of 0.25–5 ppm, and for
the low-exposure areas was 0.15 ± 0.02 ppm
(significantly different, p < 0.002). The
median for the high-exposure areas was 0.41
ppm, and the median for the low-exposure
areas was 0.125 ppm (half of the detection
limit). If the two extreme values are included,
the high-exposure group mean was 3.18 ±
1.23 ppm, and the median was 0.52 ppm
BD. The distribution of exposure measure-
ments was consistent with our expectations,
based on information from experienced work-
ers in the facility, and confirms our assign-
ment of these areas as high or low exposure. 
The average concentration of the M1
metabolite in the urine of workers in the
high-exposure areas was 2,046 ng/mg creati-
nine, compared to 585 ng/mg creatinine in
the low-exposure areas. This difference was
highly significant (p < 0.0004). The fre-
quency of HPRT mutant lymphocytes (mean
±S E) was 2.10 ± 0.2 × 10–6 in the low-expo-
sure group and 6.66 ± 1.4 × 10–6 in the high-
exposure group. This difference was also
highly statistically signiﬁcant (p < 0.0002 by
t-test and p < 0.0001 by the Wilcoxon test).
When stratiﬁed by smoking status, which is
known to affect HPRT Vf (27–29), there was
a highly signiﬁcant difference between the 19
nonsmokers in the high-exposure areas and
20 nonsmokers in the low-exposure areas (p
< 0.0005). Tobacco smokers were identiﬁed
by both questionnaire data and plasma coti-
nine levels > 20 ng/mL. In this study, the
self-reported data and the cotinine data were
concordant. The ﬁve high-exposure smokers
had a Vf of 6.1 × 10–6, almost 2-fold higher
than the ﬁve low-exposure smokers (Vf 3.3 ×
10–6), but this was not statistically signiﬁcant
(Table 2, Figure 2). 
The quality of the cultures for HPRT Vf
analysis was high. The average LI was 0.16,
and the average number of evaluatable cells
was 2.57 × 106 lymphocytes. These values
are comparable to other studies that we have
conducted (20,22,24,27). The mean LIs
were identical in the two exposure groups
(0.16), and the mean numbers of evaluatable
cells (LI × total cells) were 2.78 × 106 and
2.38 × 106 in the low- and high-exposure
groups, respectively. 
Correlation among end points. We evalu-
ated the correlation of BD exposure with
urine M1 and HPRT Vf. For subjects whose
exposure was below the detection limit (0.25
ppm), a value equal to one-half the detection
limit (0.125 ppm) was used. Figure 3 displays
the relationship between urine M1 concentra-
tion and BD exposure for those subjects who
had a detectable BD exposure (> 0.25 ppm).
As we previously explained for Figure 1, we
have excluded from Figure 3 the two individ-
uals with aberrantly high badge readings. The
lab worker with the contaminated badge had
an M1 level of only 954 ng/mg of creatinine,
and the pipeﬁtter who was wearing a respira-
tor at the time of his high exposure had an
M1 level of 2915 ng/mg of creatinine. If the
measurements from these two workers are
excluded, a fairly strong positive relationship
between exposure and urine M1 concentra-
tion can be seen. The sample correlation coef-
ficient is r = 0.68 [95% confidence interval
(CI), 0.48–0.82; p < 0.00001]. 
The relationship of HPRT Vf with mea-
surable BD exposure is displayed in Figure 4.
Again, the two individuals with very high
badge BD levels are not included. The labo-
ratory worker’s Vf was 1.14 × 10–6, and the
pipeﬁtter’s Vf was 4.54 × 10–6.These are rea-
sonable frequencies because HPRT Vf should
reflect exposure over an extended period of
time, and the unusual 1-day BD exposure
values for these two subjects are probably not
typical for these individuals. If the two high
badge values are excluded from the calcula-
tion, the sample correlation coefﬁcient is r =
0.51 (95% CI, 0.26–0.70; p = 0.0002).
The relationship between M1 and HPRT
Vf is shown in Figure 5. Each data point rep-
resents an individual who is identified with
respect to exposure group and smoking status.
Visually, there appears to be a good deal of
scatter in the data. However, the individuals
in the low-exposure group are clustered in the
lower left quadrant of the graph, and many in
the exposed group are in the upper right
quadrant. Overall, the sample correlation
coefﬁcient between the two parameters is r =
0.42 (95% CI, 0.14–0.64; p = 0.00045). The
data set was also analyzed for relationships
between the exposure and effect end points
and other parameters including alcohol use,
age, and longevity of work at this facility. No
correlations were seen between alcohol use
and HPRT Vf in any exposure group, but
most users of alcohol claimed to be light or
moderate drinkers. Both age and longevity
were correlated with HPRT Vf in only one
subgroup, the ﬁve smokers in the high-expo-
sure group. The sample correlation coefﬁcient
was r = 0.93 (95% CI, 0.2–0.99; nonsigniﬁ-
cant) for age and 0.98 (95% CI, 0.73–0.99; p
= 0.0012) for longevity in the workplace.
There was no correlation of HPRT Vf with
Articles • Ammenheuser et al.
1252 VOLUME 109 | NUMBER 12 | December 2001 • Environmental Health Perspectives
Table 2. Group means for BD exposure, urine M1 metabolite, and HPRT Vf by exposure group, with HPRT
Vf subdivided by smoking status
Butadiene Urine M1 (ng/mg HPRT HPRT
Exposure BD exposure M1 creatinine) Smoking Vf Vf  × 10–6
group (n) (ppm) (± SE)a (n)( ± SE) status (n)( ± SE)
High 22b 1.48 (0.37)* 24 2,046 (348)** Nonsmoker 19 6.8 (1.2)**
Smoker 5 6.1 (2.0)
Low 24c 0.15 (0.02) 23d 585 (98) Nonsmoker 20 1.8 (0.2)
Smoker 5 3.3 (0.5)
aValues shown are 8-hr time-weighted average exposure; results returned as below the detection limit were set to 0.125
ppm (half the detection limit) for calculation. bExcludes two unusually high values of 20.8 and 23.0 ppm that are discussed
in the text; if those values are included, the average BD exposure is 3.18 ± 1.23 ppm. cBD exposure data were not
obtained from one subject (M1 595 ng; Vf 2.82 × 10–6). dTwo subjects failed to provide urine samples. *Signiﬁcantly differ-
ent from low-exposure group, p < 0.002. **Signiﬁcantly different from low-exposure group, p < 0.0005.
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Figure 2. The distribution of frequencies of HPRT
mutant lymphocytes is shown, stratiﬁed by expo-
sure group and smoking status. Abbreviations: NS,
nonsmoker; S, smoker. The high-exposure group
consisted of workers in the tank farm, reactor,
recovery, and styrene-butadiene rubber laboratory
areas; the low-exposure groups consisted of work-
ers in the blending, coagulation, shipping, control
room, and utility areas. The mean HPRT Vfs for low
exposure, nonsmokers  and high exposure, non-
smokers are signiﬁcantly different (p < 0.0005).
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Figure 1. Average exposures based on 8-hr shift
time-weighted average measurements. Error bars
indicate SD. The number of samples in each work
area are shown above the bars. The low-expo-
sure areas consisted of the coagulation, baling,
shipping, control room, and utility areas. All low-
exposure areas samples were below the detec-
tion limit of 0.25 ppm, so a value of 0.125 ppm was
assigned. The two extreme values described in
the text are omitted. They were values from a
worker in the styrene-butadiene rubber (SBR) lab-
oratory and a maintenance mechanic working in
several locations. age or longevity in the nonsmokers or in the
overall group. This is important because the
average age and longevity were somewhat
greater in the high-exposure group than in the
low-exposure group (Table 1). 
Discussion
The use of biological markers offers a method
for assessing human exposure to potentially
hazardous agents that facilitates the evaluation
of exposures at the time of their occurrence.
The biological events that are used as bio-
markers reﬂect different stages in the contin-
uum of events that occur between human
exposure to a chemical and a resulting adverse
health outcome. Because these biomarkers
typically respond to exposure in a much larger
proportion of an exposed population than the
fraction that eventually becomes ill, bio-
marker studies can be conducted in much
smaller populations than would be required
for epidemiologic studies based on morbidity
or mortality as an outcome. The Committee
on Biological Markers of the National
Research Council has classified biological
markers into categories of exposure, effect,
and susceptibility (30). 
In this study, we compared biological
markers of both exposure (urine M1) and
effect (HPRT mutation) to exposures mea-
sured with passive badge dosimeters.
Participating workers were categorized into
areas of high and low exposure to BD based
on historical data. The exposure sampling
showed that average exposures in the desig-
nated high-exposure areas were 1.48 ppm of
BD, whereas the exposures in the designated
low-exposure areas were almost all below the
quantitation limit for the assay method used
(about 0.25 ppm). The BD levels in the
high-exposure areas can be compared to the
current OSHA permissible exposure limit of
1 ppm. At the time the study was conducted,
however, the standard was 1,000 ppm. 
At the average exposure level of 1.48 ppm
(excluding two extreme values), the two bio-
markers that we used detected statistically
signiﬁcant increases in the concentration of
the M1 metabolite of butadiene in urine, and
the HPRT variant frequency in lymphocytes.
The average M1 concentration was about 3-
fold greater in the high-exposure group than
in the low-exposure group. The magnitude
of the difference in the HPRT Vf between
the two groups was also about 3-fold. The
BD metabolite biomarker in urine docu-
mented that the workers in the high-exposure
areas received a greater internal exposure to
BD than did workers in low-exposure areas.
The increased frequency of HPRT mutant
lymphocytes indicated that BD exposure was
associated with an increased level of genetic
damage, resulting in the fixation of muta-
tions. Together these results suggest that
occupational exposure to BD at about 1–3
ppm can be detected with biomarkers and
that this exposure is associated with the
induction of mutations in lymphocytes. 
We found that the three main end
points, measuring external and internal BD
exposure and mutation as an effect of expo-
sure, were correlated with each other. The
correlations between the end points were
positive, with coefficients in the range of
0.4–0.6. It is not surprising that the correla-
tions were not stronger. The measurement
of BD levels in the air using personal organic
vapor monitors provides a measure of the
worker’s potential exposure to BD, but sev-
eral factors may influence the relationship
between the exposure measured by the badge
dosimeter and by the output of the M1
metabolite in the urine. The badge is near
the face but may not accurately reflect the
breathing zone concentration under all cir-
cumstances. As we observed in one instance,
a spill of BD-saturated liquid resulted in a
very high badge reading, which was not
reflected in the concentration of urinary
metabolite. 
The activities of the worker may influ-
ence the absorption of BD from the air.
High levels of exertion would increase respi-
ratory rate and volume and increase the
amount of BD absorbed in a unit of time.
The timing of exposure would also inﬂuence
the relationship between the exposure mea-
sured in the air and the concentration of the
urinary metabolite. The time of peak excre-
tion of metabolites after exposure to BD has
not been determined in humans. However,
BD from an exposure that occurred during
the early part of the work shift would proba-
bly be excreted, in part, before the end of the
shift when the urine sample was obtained. A
better correspondence between exposure and
the urine metabolite would probably be
obtained if all the urine voided over a 24-hr
period, beginning at the start of the work
period, were analyzed. 
Finally, it should be noted that all work-
ers excreted at least a minimal amount of the
M1 metabolite. In our first study of BD
exposure, subjects who did not work at all
with BD excreted a similar concentration of
M1 (20). This raises the possibility that
some M1 is derived from either exogenous
or endogenous sources other than BD (23).
The relationship among the M1 concen-
tration, air concentration of BD, and the
HPRT Vf also shows substantial variability.
This is not unexpected because of the timing
of the manifestation of these measurements.
The badge dosimeter measures the exposure
during a speciﬁc exposure period, which was
one 8-hr shift in this study. The urinary
metabolite probably measures exposure pri-
marily on the day of specimen collection,
and not more than 1 or 2 days before collec-
tion. The time period over which HPRT
mutant lymphocytes become manifest after
an exposure, under these conditions, is not
well characterized. It is known from prospec-
tive studies of patients receiving mutagenic
chemical or radiation therapies that the
mutant phenotype is not manifested until
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Figure 3. Relationship between the 8-hr time-
weighted-average exposure to BD and the urine
M1 metabolite (ng/mg creatinine). Only samples
with BD levels above the detection limit (0.25
ppm) are shown, and two extremely high expo-
sures are excluded as described in the text. The
sample correlation coefﬁcient for the data shown
is r = 0.68 (p < 0.00001).
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weighted-average BD exposure and the HPRT Vf.
Only samples with BD levels above the detection
limit (0.25 ppm) are shown, and two extremely high
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Figure 5. Relationship between the M1 urine
metabolite concentration (ng/mg creatinine) and
the HPRT Vf. The exposure group, as described in
the text and in Figure 2, and smoking status are
indicated. The overall sample correlation coeffi-
cient is r = 0.42 (p = 0.0045).
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M1 urine metabolite (ng/mg creatinine)1–2 weeks after exposure. Also, after an
acute exposure to mutagens, the frequency
of mutants declines to levels far below the
peak level within a few months (26,28).
However, the effects of chronic exposure at
relatively low doses may be different because
low exposures do not produce major cyto-
toxic effects on lymphocyte populations. A
study of former smokers showed that the
HPRT Vf was similar in never-smokers and
former smokers, but almost all of the former
smokers had abstained from smoking for 5
years or more (27). Memory T-lymphocytes
may persist in circulation for most of the life
span of an individual. It is thus possible that
some mutant lymphocytes attributable to
occupational exposure could accumulate
over an extended, but uncharacterized,
period of time. The exposure that was mea-
sured on a single day by badge dosimetry
may not reﬂect the cumulative exposure for
the worker over a longer period of time. In
subsequent studies multiple measurements
of BD exposure were made over a longer
period of time (31). The fact that a positive
correlation was observed between exposure,
measured both externally and internally, and
HPRT Vf indicates that occupational expo-
sure to BD did produce mutagenic effects. 
Several factors have the potential to bias
the results of the study, particularly with
respect to the mutation biomarker. The two
best characterized inﬂuences on the frequen-
cies of HPRT mutants are smoking (24,27,29)
and age (29,32). In earlier studies, smoking
increased the HPRT Vf about 3-fold over the
background rate. In this study we observed
an increase of about 2-fold in low-exposure
smokers as compared to low-exposure non-
smokers. High-exposure smokers had about
the same HPRT Vf as high-exposure non-
smokers. However, there was considerable
variation among the workers in their tobacco
usage. The number of cigarettes usually
smoked per day ranged from 6 to 40, and
cotinine values ranged from 132 ng to 625
ng/mL of plasma. Mean tobacco use was
about equal between the low- and high-expo-
sure workers, but BD exposure in the five
high-exposure smokers was only 0.64 ppm
compared to 1.48 ppm for all of the high-
exposure workers. Although smoking proba-
bly contributed to the overall frequency of
mutants in the high-exposure smokers, the
effect may have been offset by the lower than
average BD exposure in this subgroup. 
With age, the frequency of HPRT mutant
lymphocytes increases slowly. In the autoradi-
ographic assay the rate of increase is about
0.04 × 10–6 per year (29). In the cloning assay
the effect of age is a little stronger (32). We
evaluated the effect of age in the workers in
this study, but found no overall effect of age
on HPRT Vf. However, in one subgroup, the
high-exposure smokers, strong correlations of
HPRT Vf with both age (r = 0.93) and
longevity in the workplace (r = 0.98) were
observed. This subgroup contained only ﬁve
individuals, and the association was not
observed in other subgroups, so the signifi-
cance of this observation is not clear. If some
HPRT mutant lymphocytes persist for a long
period of time, they might accumulate with
years of exposure to both butadiene and the
mutagens in cigarette smoke.
Lymphocytes from some of the non-
smoking, high-exposed workers were also
assayed for HPRT mutant frequencies using
the cloning assay (33,34). Clones of mutant
lymphocytes were expanded and analyzed to
determine what types of mutations they con-
tained. They were compared to clones of
mutant lymphocytes in control subjects who
did not work in the petrochemical industry.
Results of this study have been published
separately (35). The mutant frequency (Mf)
in the cloning assay in 10 high-exposure
workers was significantly higher (p < 0.05)
than the Mf in 11 controls (Mf ± SD =
17.63 + 5.05 × 10–6 vs. 8.47 + 2.88 × 10–6,
respectively). Autoradiographic HPRT assays
of lymphocytes from the same samples also
showed a signiﬁcant increase in BD-exposed
workers (Vf 6.86 ± 3.25 × 10–6) compared to
unexposed controls (2.36 ± 1.04 × 10–6 ;
p < 0.05). Results from the two types of
HPRT assays, performed on split samples,
were significantly correlated (r = 0.70,
p < 0.001) (36). In BD-exposed workers, a
significantly higher proportion of mutant
clones contained deletions of one or more
exons (p < 0.05). A 2-fold, but nonsigniﬁcant,
increase in the proportion of base substitution
mutations at A-T base pairs was observed,
and a higher proportion of frameshift muta-
tions was seen in the exposed group (p < 0.05)
(35). These observations are consistent with
the types of mutations induced by BD and
DEB in cell culture (16,37) and in animals
(11,12,17,38). The observation of this pat-
tern of mutation supports the idea that at
least some of the mutations observed in these
workers are attributable to the mutagenic
activity of butadiene. 
An obvious question raised by the obser-
vation of a mutagenic effect associated with
exposure to a known carcinogen is whether
workers exposed to low concentrations of
BD have an elevated cancer risk. Concerns
about cancer risk must be tempered for sev-
eral reasons. First, a direct link between
increased frequencies of HPRT mutant lym-
phocytes and elevated cancer risk has not
been established. The only genetic bio-
marker for which such a link exists at this
time is structural chromosome aberrations.
Prospective studies have been conducted that
demonstrate that individuals who developed
cancer had previously demonstrated higher
rates of chromosome damage (39,40).
Despite the lack of similar prospective stud-
ies of somatic cell mutations in humans, the
role of mutation in carcinogenesis is well
known. Documentation of an increased fre-
quency of mutant lymphocytes that can be
attributed to exposure is cause for concern.
These effects, however, must be considered
on a population rather than on an individual
basis. The biomarker results for an individ-
ual cannot be used to predict his or her
future disease risks; however, the average
results for the population may be indicative
of risks to the population as a whole. Also,
the results of a biomonitoring study do not
reflect the cumulative effect of long-term
exposure, and recent exposures might not be
typical of long-term experience for an indi-
vidual. Other exposures, such as smoking,
may contribute to the response of the effect
biomarker. In addition, the genetic charac-
teristics of individuals will quite likely inﬂu-
ence their response to butadiene exposure.
Such characteristics were not analyzed in this
population; however, in continuing studies
of SBR workers, we are evaluating genetic
polymorphisms in genes encoding several
biotransformation enzymes (41). 
The results of this study are consistent
with our earlier studies of workers in a buta-
diene monomer production facility, in
which we observed an increase in HPRT Vf
in workers in production areas. This increase
in the frequency of mutant lymphocytes was
correlated with an increase in the M1 urine
metabolite (20,22). In continuing studies we
are enlarging the study population and mak-
ing a more detailed assessment of exposure
using a more sensitive method for the mea-
surement of external exposure. Our results at
this point consistently indicate that exposure
to BD at about 1–3 ppm is associated with
an increase in HPRT mutant frequency. 
Although our genetic biomonitoring
studies of BD-exposed workers in Texas have
been consistently positive to date, other stud-
ies have not detected mutagenic effects of
occupational exposure to BD. A population
of BD-exposed workers in China was recently
evaluated (42). Reported exposures were
somewhat higher than we observed in our
study, with some very high episodic exposures
associated with activities such as pump repair
and process sample collection. Most of the
male subjects in the study smoked, but none
of the women used tobacco. Hayes et al. (42)
found no difference between the butadiene-
exposed group and the control group in the
frequency of HPRT mutants using the
cloning assay. The Mfs in both the exposed
and control groups averaged 15–20 × 10–6,
which is much higher than the Mfs for the
unexposed control group in our cloning assay
Articles • Ammenheuser et al.
1254 VOLUME 109 | NUMBER 12 | December 2001 • Environmental Health Perspectivesstudy (35). Tates et al. (43) studied workers
in a butadiene monomer production unit
near Prague in the Czech Republic. The
median BD exposure, measured in 1994 for
19 workers, was 0.24 ppm, which is less than
the median for the high-exposure workers in
the present study. Using the cloning HPRT
assay, no signiﬁcant difference was observed
between the Mfs of exposed workers and con-
trol subjects. In this case the HPRT Mfs for
control subjects were in the same range as our
cloning study, but the Mfs for BD-exposed
subjects were relatively low as well. It is not
clear why we have repeatedly observed an
association between BD exposure and fre-
quencies of HPRT mutant lymphocytes in
our studies while other investigators have not.
In the case of the samples from the current
study, significant increases in mutant fre-
quency were measured using both the autora-
diographic and cloning assays (35). In this
study, correlations among BD exposure,
internal exposure, and genotoxicity were
clearly observed in a facility where exposures
were near the current OSHA permissible
exposure limit. Because of the role of muta-
tion in carcinogenesis, continued study of the
potential carcinogenic effects of occupational
exposure to butadiene, and consideration of
the classiﬁcation of this important industrial
chemical as a carcinogen are warranted. 
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